Cullinan Therapeutics
CGEM
96 hedge funds and large institutions have $396M invested in Cullinan Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 22 reducing their positions, and 13 closing their positions.
333% more call options, than puts
Call options by funds: $13K | Put options by funds: $3K
91% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 22
47% more capital inflows, than outflows
Capital inflows: $19M | Capital outflows: $13M
0.85% more ownership
Funds ownership: 81.18% → 82.03% (+0.85%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
3% less funds holding
Funds holding: 99 → 96 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
+$2.38M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$2.27M |
| 3 |
Tang Capital Management
San Diego,
California
|
+$2.25M |
| 4 |
BlackRock
New York
|
+$1.6M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baupost Group
Boston,
Massachusetts
|
-$5.51M |
| 2 |
Goldman Sachs
New York
|
-$1.93M |
| 3 |
EcoR1 Capital
San Francisco,
California
|
-$1.31M |
| 4 |
Morgan Stanley
New York
|
-$768K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$520K |
CGEM Hedge Fund Activity: Q4 2022 in Review
96 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2022, worth a combined $396M — down 17% from $475M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CGEM and 12 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 42 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $2.38M. The largest seller was Baupost Group, exiting entirely with an estimated $5.51M sold.
- 96 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2022, down from 99 in Q3 2022.
- Funds reported $396M of Cullinan Therapeutics stock for Q4 2022, down 17% quarter-over-quarter.
- 12 funds opened new Cullinan Therapeutics positions in Q4 2022 and 13 closed out, a net change of -1 holder.
- The largest Cullinan Therapeutics buyer in Q4 2022 was Woodline Partners, an estimated $2.38M added.
- The largest Cullinan Therapeutics seller in Q4 2022 was Baupost Group, an estimated $5.51M sold.
Based on aggregated 13F filings for Q4 2022.